These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 24612662)
1. Burden of disease matters when it comes to systemic therapy for prostate cancer. Harrison MR; Armstrong AJ Eur Urol; 2015 Mar; 67(3):448-50. PubMed ID: 24612662 [No Abstract] [Full Text] [Related]
2. Re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7. Lu K Eur Urol; 2015 Sep; 68(3):e55-6. PubMed ID: 25865060 [No Abstract] [Full Text] [Related]
3. Reply to Kevin Lu's letter to the editor re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7. Azad AA; Chi KN Eur Urol; 2015 Sep; 68(3):e57-8. PubMed ID: 25864159 [No Abstract] [Full Text] [Related]
4. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Azad AA; Eigl BJ; Leibowitz-Amit R; Lester R; Kollmannsberger C; Murray N; Clayton R; Heng DY; Joshua AM; Chi KN Eur Urol; 2015 Mar; 67(3):441-7. PubMed ID: 24508071 [TBL] [Abstract][Full Text] [Related]
5. Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events? Geynisman DM; Ross EA; Plimack ER Eur Urol; 2015 Oct; 68(4):578-80. PubMed ID: 26116295 [No Abstract] [Full Text] [Related]
6. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882 [TBL] [Abstract][Full Text] [Related]
7. Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward? Suzman D; Eisenberger M Eur Urol; 2014 Nov; 66(5):826-8. PubMed ID: 24751214 [No Abstract] [Full Text] [Related]
8. Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate. Petrioli R; Francini E; Laera L; Fiaschi AI; Ponchietti R; Roviello G Cancer Chemother Pharmacol; 2015 Sep; 76(3):439-45. PubMed ID: 26082421 [TBL] [Abstract][Full Text] [Related]
9. Counterpoint: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Abiraterone. Jones RJ Oncology (Williston Park); 2018 May; 32(5):223, 226-7, 247. PubMed ID: 29847852 [No Abstract] [Full Text] [Related]
10. Prolonged biochemical response after discontinuation of orteronel (TAK-700) in a patient with metastasized castration-resistant prostate cancer. Manenschijn L; Hamberg P Acta Oncol; 2016 May; 55(5):656-8. PubMed ID: 27046420 [No Abstract] [Full Text] [Related]
11. STAMPEDE-ing towards androgen biosynthesis inhibition for treatment of high-risk hormone-naïve prostate cancer: changing the LATITUDE. Klaassen Z; Murphy DG BJU Int; 2018 Jan; 121(1):9-11. PubMed ID: 28990349 [No Abstract] [Full Text] [Related]
12. TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer. Qin S; Liu D; Kohli M; Wang L; Vedell PT; Hillman DW; Niu N; Yu J; Weinshilboum RM; Wang L Clin Pharmacol Ther; 2018 Jul; 104(1):201-210. PubMed ID: 29027195 [TBL] [Abstract][Full Text] [Related]
13. Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate? Ohlmann CH Prostate Cancer Prostatic Dis; 2024 Mar; 27(1):155-156. PubMed ID: 36446944 [No Abstract] [Full Text] [Related]
14. Point: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Chemotherapy. Isaacsson Velho P; Eisenberger MA Oncology (Williston Park); 2018 May; 32(5):223-6. PubMed ID: 29847851 [No Abstract] [Full Text] [Related]
15. Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons. Hamid AA; Morris MJ; Davis ID Eur Urol Focus; 2019 Mar; 5(2):165-167. PubMed ID: 30559064 [TBL] [Abstract][Full Text] [Related]
16. [Study on the therapy of castration-resistant prostate cancer : Randomized phase II study of abiraterone acetate with LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naive castration-resistant prostate cancer (SPARE) - AP 67/11 of the Association of Urogenital Oncology (AUO)]. Rexer H Urologe A; 2016 May; 55(5):665-7. PubMed ID: 27138632 [No Abstract] [Full Text] [Related]
17. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer. Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A; Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031 [TBL] [Abstract][Full Text] [Related]
18. The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel? Aoun F; El Rassy E; Sleilaty G; Assi T; Bakouny Z; Kattan J Future Oncol; 2017 Dec; 13(30):2785-2790. PubMed ID: 29188727 [TBL] [Abstract][Full Text] [Related]
19. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831 [TBL] [Abstract][Full Text] [Related]
20. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate. Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]